Related Experiment Video
Updated: Apr 23, 2026

Methods to Discover Alternative Promoter Usage and Transcriptional Regulation of Murine Bcrp1
Published on: May 27, 2016
Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation
Adeline Vitaliano-Prunier1, Juliane Halftermeyer1, Julien Ablain1
1Université Paris Diderot, Sorbonne Paris Cité, Paris, France; INSERM Unité Mixte de Recherche 944, Equipe Labellisée par la Ligue Nationale contre le Cancer, Institut Universitaire d'Hématologie, Paris, France; Centre National de la Recherche Scientifique, Unité Mixte de Recherche 7212, Hôpital St. Louis, Paris, France;
Abstract:
PML/RARA, a potent transcriptional inhibitor of nuclear receptor signaling, represses myeloid differentiation genes and drives acute promyelocytic leukemia (APL). Association of the retinoid X receptor-α (RXRA) coreceptor to PML/RARA is required for transformation, with RXRA promoting its efficient DNA binding. APL is exquisitely sensitive to retinoic acid (RA) and arsenic trioxide (arsenic), which both trigger cell differentiation in vivo. Whereas RA elicits transcriptional activation of PML/RARA targets, how arsenic triggers differentiation remains unclear. Here we demonstrate that extinction of PML/RARA triggers terminal differentiation in vivo. Similarly, ablation of retinoid X receptors loosens PML/RARA DNA binding, inducing terminal differentiation of APL cells ex vivo or in vivo. RXRA sumoylation directly contributes to PML/RARA-dependent transformation ex vivo, presumably by enhancing transcriptional repression. Thus, APL differentiation is a default program triggered by clearance of PML/RARA-bound promoters, rather than obligatory active transcriptional activation, explaining how arsenic elicits APL maturation through PML/RARA degradation.
Insights
Acute promyelocytic leukemia (APL) differentiation is triggered by removing the PML/RARA oncoprotein, not by active gene activation. Clearing PML/RARA from DNA allows myeloid differentiation, explaining arsenic
Area of Science:
- Molecular Biology
- Cancer Biology
- Hematology
Background:
- The PML/RARA oncoprotein drives acute promyelocytic leukemia (APL) by inhibiting myeloid differentiation.
- Retinoid X receptor-alpha (RXRA) binding to PML/RARA is crucial for its oncogenic function and DNA binding.
- APL cells are sensitive to retinoic acid (RA) and arsenic trioxide, which induce differentiation.
Purpose of the Study:
- To elucidate the mechanism by which arsenic trioxide induces APL cell differentiation.
- To investigate the role of PML/RARA clearance and retinoid X receptors in APL pathogenesis and differentiation.
Main Methods:
- Investigated the effect of PML/RARA extinction on myeloid differentiation in vivo.
- Examined the impact of retinoid X receptor ablation on PML/RARA DNA binding and APL cell differentiation ex vivo and in vivo.
- Assessed the role of RXRA sumoylation in PML/RARA-mediated transformation.
Main Results:
- PML/RARA extinction triggers terminal myeloid differentiation in vivo.
- Ablation of retinoid X receptors disrupts PML/RARA DNA binding, inducing APL cell differentiation.
- RXRA sumoylation enhances PML/RARA's transcriptional repression and oncogenic transformation.
Conclusions:
- APL differentiation is a default program initiated by the clearance of PML/RARA from target gene promoters.
- Arsenic induces APL maturation by promoting PML/RARA degradation, leading to the release of repressed myeloid differentiation genes.
- Targeting PML/RARA clearance offers a therapeutic strategy for APL.
Related Concept Videos
RNA Polymerase II Accessory Proteins
Master Transcription Regulators
The Eukaryotic Promoter Region
Abnormal Proliferation

